Introduction
Neuropeptide S (NPS) is a recently identified endogenous ligand of an orphan G protein coupled receptor (Xu et al., 2004) . This peptide appears to have arousing properties in such that intraventricular NPS injections increase locomotor activity and wakefulness and activate the HPA axis (Reinscheid, 2008; Rizzi et al., 2008; Smith et al., 2006; Xu et al., 2004) . In addition, NPS injections increase c-Fos in lateral hypothalamic hypocretin (also known as orexin) neurons (Niimi, 2006) , which play a critical role in arousal (Boutrel et al., 2010; Sutcliffe and de Lecea, 2002) .
The NPS receptor appears to be expressed throughout the brain (Leonard and Ring, 2011; Xu et al., 2007) , including in the regions that are associated with reward processes (Ikemoto, 2010) : the ventral tegmental area, olfactory tubercle, bed nucleus of stria terminalis, diagonal band, paraventricular thalamic nucleus, preoptic area, lateral and posterior hypothalamic areas, periaqueductal gray, median and dorsal raphe nuclei and parabrachial nucleus. This pattern of receptor expression led us to ask whether arousing effects of intraventricular NPS administration are reward-related.
In this study, we examined whether intraventricular NPS was selfadministered and induced conditioned place preference in rats. We also examined effects of dopamine receptor antagonists and hypocretin receptor antagonists on NPS self-administration. Finally, we examined whether repeated NPS injections have sensitizing effects on locomotor activity.
Materials and Methods

Animals
Male Wistar rats (N=98) (Harlan, Dublin, VA, USA) were maintained in a temperature and humidity controlled room on a reversed 12-h lightdark cycle (lights on at 21.00 h) with unlimited access to food and water except during testing. They weighed 280-350 g at the time of surgery and were individually housed after surgery. All experimental procedures were approved by the Animal Care and Use Committee of the Intramural Research Program, National Institute of Drug Abuse, and were consistent with the National Institutes of Health guidelines. We made every effort to minimize animal suffering and to reduce the number of animals used in this study.
The hypocretin-1 (also known as orexin-1) receptor antagonist SB 334867 (1-(2-methylbenzoxazol-6-yl)-3-[1,5]naphthyridin-4-yl urea; Tocris Cookson, Ellisville, MO, USA) was dissolved in 10% (2-hydroxypropyl)-β-cyclodextrin/2% dimethyl sulfoxide solution (Sigma-Aldrich).
Stereotaxic Surgeries
Under sodium pentobarbital (31 mg/kg, i.p.) and chloral hydrate (142 mg/kg, i.p.) anesthesia, a single unilateral guide cannula (24-gauge) was implanted in each rat aiming at the lateral ventricle and permanently fixed to the skull with acrylic dental cement. Stereotaxic coordinates for the lateral ventricle were 0.0 mm anterior to bregma, 1.5 mm lateral to the midline, 4.0 mm ventral to the skull surface. Rats were left undisturbed for several days after the surgery.
General Procedures
Procedure for Intraventricular Experimenter-administered Injections
Three days before the start of experiments, each rat was taken to a testing room and placed in a 30 cm diameter cylinder. An injection cannula (31 gauge) was inserted into the implanted guide cannula. The tip of the injection cannula extended beyond the tip of the guide by 1.0 mm. Each rat received an angiotensin solution (50 ng in 1 μl) that was delivered by a syringe pump at a constant rate over 60 s, with an additional 30 s before the injection cannula was removed. The rat was then returned to its home cage. We performed this intraventricular angiotensin injection, known to cause immediate and intense water consumption, to validate the placement of the cannula assembly aimed into the lateral ventricle. Rats that did not immediately begin drinking were eliminated from the following experiments involving NPS injections. NPS was delivered into the lateral ventricle with a 2.2 μl volume at a constant rate over 60 s, with an additional 30 s before the injection cannula was removed.
Procedure for Intraventricular Self-administration
Experiments were conducted in standard operant chambers (30 × 22 × 24 cm; Med Associates, St Albans, VT, USA) equipped with a lever (45 mm wide × 2 mm thick protruding 20 mm from the wall) and a cue light located just above the lever. The intraventricular guide cannula was inserted with an injection cannula (31 gauge), which was connected by polyethylene tubing to a micropump consisting of a drug reservoir and step motor (Ikemoto and Sharpe, 2001 ) that hung a few millimeters above the rat's head. When activated, the micropump's step motor turned its shaft in six incremental steps (9°per step) over 5 s, driving its threaded shaft into the drug reservoir and pushing a 75 nl volume out of the reservoir into the brain. A response on the lever activated the micropump and the cue light for 5 s followed by a 55 s time-out period, during which lever pressing produced no programmed consequence. In addition, we monitored each rat's gross somatomotor activity (referred to as locomotion) during selfadministration sessions by quantifying the rotation (Roto-Rat, Med Associates) of the electrical swivel for the microinjection pump. Each session lasted 90 min, and sessions were separated by a day.
Experiment 1: Concentration-dependent Effects of NPS Self-administration
Experimentally-naïve rats (N= 9) received vehicle (75 nl/infusion) in sessions 1 and 5, and NPS (3.39 pmol/infusion) in sessions 2-4 (acquisition phase), followed by vehicle (session 5) and increasing doses of NPS (0.339, 3.39 and 33.9 pmol/infusion) in sessions 6-8, respectively (dose-response test). During self-administration sessions, locomotor activity was assessed with the Roto-Rat device, except that of the first rat we tested, since the device had not been set up then.
2.6. Experiment 2: Effects of the Dopamine Receptor Antagonist SCH 23390 on NPS Self-administration A group of rats (N = 6) was first trained to self-administer NPS (3.39 pmol/injection) in sessions 1 and 2. Then, they were pretreated with SCH 23390 (0.025 mg/kg, i.p.) or saline (1 ml/kg, i.p.) 30 min before a self-administration session. They self-administered for vehicle in sessions 3 and 4 and NPS (3.39 pmol/infusion) in sessions 5 and 6. The order of testing the effects of SCH 23390 or saline was counterbalanced among the rats.
2.7. Experiment 3: Effects of the Hypocretin-1 Receptor Antagonist SB 334867 on NPS Self-administration
In Session 1, experimentally-naïve rats (N = 6) received SB 334867 (a hypocretin-1 receptor antagonist; 20 mg/kg, i.p.) or vehicle (10% 2-hydroxypropyl-β-cyclodextrin/2% dimethyl sulfoxide; 1 ml/kg, i.p.) 30 min before they were placed in the chamber for self-administration of NPS (3.39 pmol/infusion). In session 2, the i.p. injections of SB 334867 and vehicle were reversed among the rats. The order of testing the effects of SB 334867 or vehicle was counterbalanced among the rats. In this experiment, rats were not trained to self-administer NPS prior to these tests, because we found in experiments 1 and 2 that rats reliably initiate self-administration of NPS without prior training.
Experiment 4: Place Conditioning Induced by Intraventricular NPS
Experimentally naïve rats were used for this experiment. The place conditioning chamber consisted of two compartments (21 × 21×28 cm) linked by a connecting area (21 × 21× 12.5 cm), and a sliding door separated each compartment from the connecting area (Med Associates). The two compartments differed in wall color (black vs. white), floor type (net vs. grid) and lighting; the amount of light was adjusted so that the rats did not prefer one compartment over the other prior to place conditioning. We used an "unbiased" procedure, in which drug and vehicle injections were randomly assigned between the two compartments without consideration of rats' original place preference. In sessions 1 (pre-conditioning) and 10 (post-conditioning), rats were not given injections and were confined individually in the connecting area of the chamber for 30 s. They were then allowed to freely move about the chamber for 15 min with the sliding doors open. Their time spent in each compartment was recorded. Rats (N= 10-11) were assigned to one of the three groups of NPS doses (10, 100 or 1000 pmol/ injection). They received intraventricular injections of NPS or vehicle just before conditioning sessions 2-9. Then, each rat was confined in one of the compartments for 20 min with sliding doors closed. NPS injections were paired with one compartment and vehicle with the other. The order of injection treatments and the assignment of the compartments for injection treatments were counterbalanced among the rats in each dose group. Sessions were separated by a day. The place preference score was derived by subtracting the time spent in vehiclepaired compartment from that in drug-paired compartment.
Experiment 5: Locomotor Activity Facilitated by Intra-ventricular NPS
Tests were performed in locomotor chambers (40 × 40 × 30 cm; AccuScan Instruments, Columbus, OH, USA). Locomotion (horizontal distance traveled) was detected by 32 photocell pairs separated by 2.5 cm and placed 3 cm above the floor on all sides of the chamber. Rearing (frequency of vertical movements) was detected by 16 photocell pairs separated by 2.5 cm and placed 20 cm above the floor on two opposite sides of the chamber. Rats (N = 10-13) were assigned to one of four dose groups (0, 10, 100 or 1000 pmol). Each rat received an intraventricular injection of vehicle on the first day and an injection of NPS on each of 4 consecutive days. Immediately after each of these injections, each rat was placed in the locomotor chamber for 30 min during which locomotor distance and rearing frequency were recorded.
Data Analysis
Data were analyzed with either t-tests or ANOVAs followed by appropriate post-hoc tests. Details are provided in the Results section.
Results
Experiment 1: Concentration Dependent Effects of NPS Self-administration
We used a self-administration procedure assisted by visual cues. This procedure facilitates lever pressing without training rats and has been found to be useful for initial screening of potential rewarding effects of drugs. In session 1, rats obtained about 20 vehicle infusions, which were accompanied by the presentation of cue light just above the lever. Rats increased self-administration in sessions 2-4 when infusions contained NPS (3.39 pmol/infusion) (Fig. 1A) . Although the levels of NPS self-administration were modest, self-administration was reliable, as indicated by a significant session effect with one-way repeated measures ANOVA on infusions over sessions 1-4 (F 3, 24 = 5.86, P b 0.01). The numbers of NPS infusions tended to decrease over sessions 2-4, although this trend was not statistically significant.
Rats self-administered NPS in a dose-dependent manner in sessions 6-8 (Fig. 1A) . While the lowest dose of NPS (0.339 pmol/ infusion) in session 6 was not reliably self-administered more than vehicle in session 5, the higher doses of 3.39 and 33.9 pmol/injection in sessions 7 and 8 were self-administered more than vehicle in session 5. Event records suggest that NPS-experienced rats began lever-pressing as soon as the session started in sessions 5-8 (Fig. 1B) . However, these rats stopped responding after a few minutes when their responses were rewarded with infusions of vehicle or 0.339 pmol NPS. Lever-pressing was prolonged when the doses of NPS increased. These observations were confirmed by a significant dose effect with one-way repeated measures ANOVA on infusions over sessions 5-8 (F 3, 24 = 4.98, P b 0.01).
Unlike self-administration, we did not observe reliable changes in locomotor activity during sessions 5-8 (F 3, 21 = 1.99, P = 0.15, a oneway repeated measures ANOVA) in which rats displayed increasing lever pressing for NPS (Fig. 1C) . This result suggests that general arousal or hyperactivity does not explain the self-administration effects of NPS.
Experiment 2: Effects of the Dopamine Receptor Antagonist SCH 23390 on NPS Self-administration
Rats quickly increased lever pressing for NPS administration in sessions 1 and 2 (data not shown), replicating acquisition of NPS selfadministration in experiment 1. Pretreatment with the D 1 receptor antagonist SCH 23390 significantly reduced NPS self-administration (Fig. 2) . Although pretreatment with SCH 23390 also tended to reduce self-administration of vehicle, this was not statistically significant. A one-way repeated measures ANOVA on infusions shows a significant main session effect (F 3, 15 = 10.57, P b 0.001). Similar patterns of change were observed for locomotor counts as a function of the SCH 23390 treatment (a significant main treatment effect, F 3, 15 = 6.41, P b 0.01, Fig. 2 ).
Experiment 3: Effects of the Hypocretin/Orexin Receptor Antagonist SB 334867 on NPS Self-administration
Pretreatment with SB 334867 (20 mg/kg i.p.) significantly decreased NPS self-administration (t 5 =4.04, P b 0.01), whereas it did not reliably decrease locomotor activity during self-administration sessions (Fig. 3) .
Experiment 4: Place Conditioning Induced by Intraventricular NPS
To examine whether NPS injections have a positive affective effect, we employed a place conditioning procedure in which compartments' contextual cues were paired with arousing effects induced by intraventricular NPS injections. The rats receiving the high dose of NPS (1000 pmol) spent more time in the drug-paired compartment, suggesting conditioned approach, whereas the rats received the medium NPS dose (100 pmol) spent more time in the vehicle-paired side, suggesting conditioned avoidance (Fig. 4) . The low dose (10 pmol) of NPS had no reliable effect. These observations were confirmed with a significant interaction with a 3 × 2 (dose × beforeand-after conditioning) mixed ANOVA (F 2, 28 = 9.32, P b 0.001).
Experiment 5: Locomotor Activity Facilitated by Intraventricular NPS
To examine whether repeated injections of NPS are behaviorally sensitizing, we monitored locomotion and rearing after NPS injections over a few days. The medium (100 pmol) and high (1000 pmol) doses of NPS injections acutely increased locomotion and rearing, while the low dose (10 pmol) had no detectable effect (Fig. 5) . Instead of being sensitizing, the high dose of NPS injections decreased locomotion and rearing over days 2-5. When the rats received the same injection manipulation on day 12, none of the NPS doses increased locomotion or rearing more than on previous days. Thus, we did not observe any evidence of behavioral sensitization. These observations were confirmed by significant group × session interactions on locomotion (F 15,210 = 3.94, P b 0.001) and rearing (F 15,210 = 2.66, P b 0.005) with 4 × 6 (group × session) ANOVAs.
Discussion
Reward-like Effects of Intraventricular NPS
We observed that untrained rats increased cue-assisted selfadministration of intraventricular NPS when they received it for the first time, and maintained NPS self-administration for the next two sessions. In subsequent sessions, rats self-administered NPS in a dosedependent manner. These observations need to be carefully interpreted, particularly because our self-administration procedure involved not only NPS infusions, but also visual cues.
Our results on self-administration of NPS suggest that intraventricular NPS facilitates seeking responses. Sensory cues accompanied by drug administration serve as "bridges" between responding and pharmacological actions of the drug (Sorge et al., 2009 ). Cue-assisted procedures of drug self-administration make it easier for animals to learn the relationships between manipulators, actions and drug effects. Moreover, because brief presentation of visual cues is positively salient and triggers seeking responding in rats (Shin et al., 2010; Stewart and Hurwitz, 1958) , this procedure was used to facilitate lever pressing, thereby, learning the association between lever pressing and the delivery of NPS. However, this procedure is only useful as an initial screening tool for seeking facilitation properties of drugs, because this procedure does not clearly indicate what rats respond for, in this case, NPS infusions or visual cues. In addition, the fact that intraventricular NPS promotes locomotor activity and wakefulness (Xu et al., 2004) makes it unclear whether increased lever pressing was due to enhanced seeking or "general" arousal. In our previous study, however, we demonstrated that as far as amphetamine is concerned, seeking facilitation effects can be dissociated from general arousal: Relatively high doses of amphetamine that elicited intense locomotor activity diminished seeking responses (Shin et al., 2010) , using the identical lever press procedure employed in the present study. Therefore, it is tempting to interpret that increased lever pressing is seeking-related. Consistent are recent findings that intraventricular injections of NPS facilitate seeking for alcohol or cocaine (Cannella et al., 2009; Kallupi et al., 2010; Paneda et al., 2009 ).
Because our self-administration effects of NPS are rather weak, we did not further use self-administration procedures to determine if rats can learn to seek NPS infusions. Instead, we conducted the place conditioning experiment. Our place conditioning results provide partial support for intraventricular NPS being sought by rats (i.e., positive reinforcement). Rats increased time in the compartment paired with intraventricular injections of 1000 pmol NPS, suggesting conditioned approach for NPS, whereas they decreased time in the compartment paired with 100 pmol NPS, suggesting conditioned aversion for NPS. It is difficult to compare effects between selfadministration and place conditioning, since NPS were delivered with different procedures between them. Having that said, the 3.4-pmol dose was self-administered roughly 30 times in average, adding up to roughly 100 pmol, which was the dose that induced conditioned aversion. The 34-pmol dose was also self-administered roughly 30 times, adding up to 1000 pmol, which was the dose that induced conditioned approach. Therefore, it is difficult to reconcile the data between self-administration and place conditioning procedures with respect to affective properties of NPS. To understand mechanisms through which NPS exert positive and negative affective (i.e., reinforcing) effects, additional research is needed.
Cue-assisted Self-administration of NPS Depends on Intact Dopamine and Hypocretin Systems
A low dose of SCH 23390 (0.025 mg/kg, i.p.) decreased lever presses for NPS. We also found a strong trend that SCH 23390 decreased lever pressing under the control condition in which responding was maintained by visual cues without NPS infusions. This effect is not surprising in light of the previous findings that responding maintained by salient stimuli is readily decreased by low doses of dopamine receptor antagonists (Bardo et al., 1989; Besheer et al., 1999; Olsen and Winder, 2009) . It is probable that responding with vehicle infusions was largely maintained by visual cues and that this visual cue seeking must have depended on dopamine transmission. It is unlikely that the SCH 23390 injections disrupted behavior in a nonspecific manner, because the previous studies suggest that 0.025 mg/kg dose in rats does not impair motor process (Koob et al., 1987; Hauber, 1996) . In any case, cue-assisted self-administration of NPS appears to depend on intact dopamine transmission. Because dopamine transmission occurring in the medial part of the ventral striatum plays a critical role in reward seeking (Ikemoto, 2007; Shin et al., 2010) , the medial ventral striatum may play a critical role in cue-assisted self-administration of NPS.
We found that a dose of hypocretin-1 receptor antagonist SB 334867 decreased cue-assisted NPS self-administration, while having no reliable effect on locomotor activity. It is possible that NPS stimulates hypocretin neurons, and that this action of NPS is important for its seeking effects. As mentioned above, intraventricular NPS administration induces c-Fos in hypocretin neurons. Moreover, NPS receptor expression has been detected in the lateral hypothalamus, including a fraction of hypocretin neurons (Kallupi et al., 2010) . Because the present result is preliminary, additional investigations are needed to understand whether and how the NPS and hypocretin systems interact.
Lack of Behavioral Sensitization
Repeated NPS injections did not lead to sensitized locomotor activity. Instead, a high dose of NPS resulted in reversible tolerance to NPS injections on locomotor activity. Therefore, unlike dopaminergic or other drugs of abuse, NPS does not seem to have any influence on sensitization-related plasticity. Although repeated injections of dopaminergic drugs lead to behavioral sensitization, the mechanism through which dopaminergic drugs acutely elicit locomotion and reward appears to be different from that leading to behavioral sensitization. Dopaminergic drugs' acute locomotor and rewarding effects are mediated via their action in the ventral striatum (Ikemoto, 2002 (Ikemoto, , 2003 Ikemoto et al., 2005) , while behavioral sensitization depends on their actions in the ventral tegmental area (Kalivas and Stewart, 1991; Kalivas and Weber, 1988; Vezina and Stewart, 1990) . Therefore, unlike dopaminergic or other drugs of abuse, NPS does not seem to modulate the activity of this region in such a way to cause behavioral sensitization.
Conclusions
Intraventricular injections of NPS appear to have reward-like effects, and can facilitate seeking and elicit weak reinforcement, although these effects are not robust in any way. These effects of NPS may be mediated by its modest ability to stimulate the dopaminergic and hypocretin systems. In addition, unlike drugs of abuse, NPS appears to lack the ability to sensitize seeking-related behavior.
